Blood Brain Barrier Technologies Market

Blood-Brain Barrier Technologies Market Size (2023 to 2028)

As per our report, the Global BBB Technologies Market Size was valued at USD 673 Million in 2023 and is projected to reach USD 1820 Million by 2028, which will grow at a remarkable CAGR of 22% from 2023 to 2028. In addition, advances in biotechnology have enabled the development of versatile in-vitro, in-vivo, and in-situ blood-brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries.

The blood-brain barrier plays a vital role in protecting the brain from blood-borne diseases and toxic compounds as they help people suffering from neural diseases like brain cancer and Alzheimer's. Alzheimer's requires the development of new drugs such as recombinant protein or gene therapies; there is an excellent scope for developing new drugs for the brain as there was no new approval for new recombinant drugs by the FDA. Thus, low-weight molecule drugs and biomacromolecules such as DNA and protein are used to treat neurological diseases. There are many types of research on developing new techniques for drug entry into the brain without damaging the blood-brain barrier membrane.

Epilepsy, sclerosis, obesity, Alzheimer's, Parkinson, neurotransmitters are neurologic are a few of the areas in which several patents on the BBB technologies are being exploited for designing drugs against widespread CND disorders. Over the years, more than 16700 licenses related to BBB technologies have been granted to various industry and non-industry players, indicating R & D's pace in this burgeoning field of research. Around 62% of patents related to BBB technologies have been granted in the United States; the Asia Pacific followed this with more than 2300 patents.

COVID-19 impact on Global BBB Technologies Market:

• Lack of oxygen reaching the brain cells for a long time can damage the brain in COVID-19 patients, leading to death.
• Recent clinical studies indicate that people suffering from CNS complications are more susceptible to COVID-19 infection due to a compromised immune system.
• Several infected have been reported to suffer from mild neurological symptoms such as acute stroke and brain tumors.

The brain is one of the most extensive and intricate organs in the human body. It consists of 100 billion nerves that communicate with 100 trillion synapses. It is up of the midbrain, hindbrain, and forebrain. It is responsible for movement and thought produced by the body. In addition, it has its security system- a filtering mechanism consisting of blood vessels that allow entry of essential nutrients and block other substances known as the blood-brain barrier. The blood-brain barrier is a semi-permeable dynamic interface that separates the capillaries that carry blood to the brain and spinal cord tissue by blocking certain substances' passage. The blood-brain barrier vessels are up of specialized endothelial cells, which line brain capillaries from the vascular system, which lack the fenestration of pores and allow rapid exchange of molecules between vessels and tissues. The blood-brain barrier protects the neural tissue from harmful chemicals and maintains a stable environment.

However, this barrier is so effective at blocking the entry of foreign substances that it often prevents penetration of life-saving drugs to address issues like injuries and diseases. Therefore, the discovery of new methods allowing the effective delivery of medicines and bio-macromolecules to the central nervous system (CNS) is of immense importance for treating neurodegenerative disorders.

MARKET DRIVERS:

The growing burden related to CNS is the significant growth driving force to the global blood-brain technologies market.

Effective drug delivery across the blood-brain barrier is one of the biggest impediments to the successful treatment of CNS-related diseases and brain tumors. Around 1.5 billion people are affected by CND-related infections globally. The global CNS drug market is worth more than 125 billion USD. More than 100 drugs capable of penetrating this elusive barrier are currently being evaluated for treating CNS treatments; there are 25+ technology platforms for developing BBB penetrant drugs.

The public and private organizations are increasing the funds for the research of the blood-brain barrier technology, propelling the market growth. The research team from Kumamoto University Japan is working on developing a cyclic peptide. There is research on creating a variety of invasive and non-invasive techniques to deliver drugs through the blood-brain barrier without disrupting the membrane. The monoclonal antibody can penetrate through the blood-brain barrier.

Additionally, the growing prevalence of neurological diseases like Parkinson's, meningitis, multiple sclerosis, and encephalitis, augmenting the geriatric population and rising healthcare expenditure further accelerate market growth. Furthermore, increasing investment in R&D for developing new drugs and delivery devices, growing awareness about healthcare, and an increasing number of initiatives by various governments and affiliated associations are projected to fuel the blood-brain barrier technologies market.

MARKET RESTRAINTS:

On the other hand, intricate regulatory frameworks for the approval of drugs in most countries and inordinate approval time for medications due to insufficient knowledge of the brain are primary restraints for the market's growth. Furthermore, people in rural areas are less aware of the latest technologies, which is slowly inhibiting market demand. In addition, the lack of proper knowledge of the procedure due to fewer training programs by the government hinders the market's growth rate.

REPORT COVERAGE:

The research report on the global blood-brain barrier technologies market has been segmented and sub-segmented into the following categories.

Global blood-brain barrier technologies market - By Technology: 

• bispecific antibody RMT approach
• trojan horse approach
• increasing permeability
• passive diffusion
• other 

The increasing permeability segment is expected to dominate the market during the forecast period due to the prevalence of the technique and its use in many conditions like nearly all CNS diseases, including ischemic stroke, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, epileptic seizures, brain trauma, and diabetes mellitus, increase the BBB's permeability. 

However, the reagents segment is expected to grow during the forecast period. This rise in the segment is due to the rising research and development in the BBB studies field requiring sets of reagents for experimentation. 

Global blood-brain barrier technologies market - By Application:

• Alzheimer's disease
• epilepsy
• Parkinson's disease
• multiple sclerosis
• Hunter's syndrome
• brain cancer
• others

The Parkinsons disease segment is expected to dominate the market during the forecast period. Annually, P.D. is diagnosed in about 60,000 Americans. Over 10 million people worldwide suffer from P.D. Parkinson's disease is more common as people age, yet only 4% of cases are identified before age 50, according to estimates. As a result, more people worldwide are becoming disabled and dying from Parkinson's disease (P.D.) than from any other neurological condition. In the last 25 years, P.D. prevalence has doubled. According to 2019 estimates, there were over 8.5 million people worldwide who had P.D. According to current estimates, P.D. caused 329 000 deaths in 2019, an increase of over 100% since 2000, and 5.8 million disability-adjusted life years, an increase of 81% since 2000.

Global blood-brain barrier technologies market - By End-use:

• Hospitals
• Surgical centers
• Research Institutes
• Others

The hospital's segment is expected to dominate the market due to the developed infrastructure of hospital settings and the widespread availability of equipment and trusted professionals. The large patient influx in hospitals is another reason for their dominance. In addition, hospitals are the safest healthcare centers for BBB procedures. 

However, surgical centers and research institutes are also expected to grow significantly due to rising studies on BBB. Additionally, the rise of individual centers supporting surgeries for lower costs than large hospitals is helping the segments rise. 

Global blood-brain barrier technologies market - By Region:

North American blood-brain barrier technologies market leads the global market, given the increasing incidence of neurological diseases and augmenting the geriatric population. In 2022, North America held a 32.3% revenue share of the worldwide market, thanks to a robust healthcare system that quickly adopts new technologies. Additionally, the marker is growing because Hunter's syndrome and Alzheimer's disease are widespread in the region, especially in countries like the U.S. and Canada, and the prevalence of neurological conditions like Parkinson's disease, multiple sclerosis, meningitis, and encephalitis is rising. Furthermore, targeted therapy is also needed in the region, and the number of older adults is rising. Parkinson Canada estimates that over the past ten years, the prevalence of Parkinson's disease has increased by about 50% in Canada.

Asia Pacific shows high growth rates in the forecast period in the market, with China and India being the fastest-growing markets in the Asia Pacific. The primary driving forces for the market in emerging economies are the large pool of patients, growing awareness about the disease, improving healthcare infrastructure, and increasing government funding in the region. 

KEY MARKET PLAYERS:

Some of the promising companies operating in the Global Blood-Brain Barrier Technologies Market are Bristol-Myers Squibb Company, Pfizer, Inc., bioasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, and ArmaGen.

Several technology developers are presently focusing on integrating advanced technical features into their proprietary drug development or delivery platforms to achieve a competitive edge. An assessment of 240+ drug developers focused on Parkinson's and Alzheimer's diseases revealed that many firms are likely to partner with technology providers to leverage their BBB penetration expertise.

RECENT MARKET DEVELOPMENTS:

• In May 2020, Two papers have been published in Science Translational Medicine ("STM") by Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates designed to cross the blood-brain barrier ("BBB") for neurodegenerative diseases. The papers provide an overview of the company's Transport Vehicle ("T.V.") technology, show how therapeutic proteins can be successfully delivered to the brain at concentrations that produce strong effects, and show how biomarkers can be normalized in a disease model of Hunter syndrome.
• In May 2020, CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company focused on the development of innovative therapies for primary and metastatic cancers of the brain and central nervous system, announced it has signed a sponsored research agreement with The University of Texas MD Anderson Cancer Center about potential cancer treatment technologies, including WP1244, a novel DNA binding agent that is up to 500 times more potent than currently available therapies.
• In June 2020, Hesperos Inc., the company that invented the Human-on-a-Chip® in vitro system, announced today the release of a new peer-reviewed article that explains how the company's functional Human-on-a-Chip system can be used as a drug discovery platform to find therapeutic interventions that target the preclinical stages of Alzheimer's disease (A.D.) and mild cognitive impairment. In addition, this week's Alzheimer's & Dementia: Translational Research & Clinical Interventions featured an article titled "A human induced pluripotent stem cell-derived cortical neuron human-on-a-chip system to study A42 and tau-induced pathophysiological effects on long-term potentiation."
• In November 2022, The U.S. Patent and Trademark Office (USPTO) awarded BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) a new platform patent for a method of delivering biopharmaceuticals across the blood-brain barrier. On November 15, 2022, the patent, a part of the business's Brain Transporter patent portfolio, will go into effect. It will last until 2037.